Safety Results from OCAPI: A European Observational Cohort Study of Insulin Glulisine-treated Children Aged 6–12 Years with Type 1 Diabetes

Abstract

Objective: Data on the safety of insulin glulisine for type 1 diabetes are limited in paediatric populations. The European post-marketing Observational prospective Cohort study of children with type 1 diabetes treated with APIDRA^® (OCAPI) study evaluated the safety of insulin glulisine in children aged 6–12 years in real-life clinical practice, with a particular focus on the 6–8 years age group.

Research design and methods: OCAPI was an international, multicentre, observational, non-interventional, prospective cohort study, in which 94 participants with type 1 diabetes (6–8 years age group: n=31; 9–12 years age group: n=63) received insulin glulisine for 6 months under normal, local conditions. The primary objective was the incidence of severe hypoglycaemia in all participants.

Results: Overall incidence of severe hypoglycaemia was 6.6 events per 100 persons/year (7.2 and 6.3 events per 100 persons/year in the 6–8 and 9–12 years age groups, respectively). 12 participants (all aged 9–12 years) experienced transient injection-site reactions. No systematic hypersensitivity reactions were reported. Only 1 participant (9–12 years age group) experienced a serious class-effect risk possibly related to insulin glulisine (severe hypoglycaemia requiring an Emergency Department visit). Glycated haemoglobin levels did not change markedly throughout the study, and were inversely proportional to the risk of hypoglycaemia.

Conclusions: Insulin glulisine has a good safety profile in children with type 1 diabetes aged 6–12 years, with generally low rates of severe hypoglycaemia and few adverse reactions. These results are encouraging for its use in paediatric populations.

Key words

diabetes mellitus - type 1 - children - insulin glulisine - safety - hypoglycaemia

• References

• 1 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
• 2 Diabetes Control and Complications Trial Research Group . Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-188
• 3 Bergenstal RM, Tamborlane WV, Ahmann A et al Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363: 311-320
• 4 Braun D, Konrad D, Lang-Muritano M et al. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. Pediatr Diabetes 2008; 9: 382-387
• 5 Bulsara MK, Holman CD, Davis EA et al. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care 2004; 27: 2293-2298
• 6 Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidøre Study Group on Childhood Diabetes. Diabetes Care 1997; 20: 714-720
• 7 Nordfeldt S, Ludvigsson J. Severe hypoglycemia in children with IDDM. A prospective population study, 1992–1994. Diabetes Care 1997; 20: 497-503
• 8 O’Connell SM, Cooper MN, Bulsara MK et al. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000–2009. Diabetes Care 2011; 34: 2379-2380
• 9 Philotheou A, Arslanian S, Blatniczky L et al. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther 2011; 13: 327-334
• 10 Rewers A, Chase HP, Mackenzie T et al. “French Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287: 2511-2518
• 11 Rosilio M, Cotton JB, Wieliczko MC et al. Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care 1998; 21: 1146-1153
• 12 Wagner VM, Grabert M, Holl RW. Severe hypoglycaemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the Diabetes Control and Complications Trial – a large-scale multicentre study. Eur J Pediatr 2005; 164: 73-79
• 13 Dailey G, Rosenstock J, Moses RG et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368
• 14 Dreyer M, Prager R, Robinson A et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37: 702-707
• 15 Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother 2005; 6: 643-651
• 16 Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 304-312
• 17 Danne T, Becker RH, Heise T et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 2100-2105
• 18 de Beaufort CE, Lange K, Swift PG et al. Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009. Pediatr Diabetes 2013; 14: 422-428
• 19 Tupola S, Komulainen J, Jaaskelainen J et al. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001; 18: 654-658
• 20 Holcombe JH, Zalani S, Arora VK et al. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002; 24: 629-638
• 21 Danne T, Philotheou A, Goldman D et al. A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes 2013; 14: 593-601